Author:
Blind E.,Dunder K.,de Graeff P. A.,Abadie E.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference25 articles.
1. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. Press release, 23 September 2010. Available from www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf
2. Cohen D (2010) Rosiglitazone: what went wrong? BMJ 341:c4848
3. EMEA (2000) European Public Assessment Report (EPAR) initial marketing authorisation documents–Avandia–Scientific Discussion. Available from www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000268/WC500029103.pdf [containing amendments up to 2004]
4. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471
5. Drazen JM, Morrissey S, Curfman GD (2007) Rosiglitazone—continued uncertainty about safety. N Engl J Med 357:63–64
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献